Jefferies Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Analyst Day: Controversial...Yet An Excellent Investment

Article Stock Quotes (1) Comments (0)

Jefferies maintains a 'Buy' on Valeant Pharmaceuticals (NYSE: VRX) price target of $63.00 (from $75.00).

Analyst, Corey Davis, said, "After what we viewed as an excellent analyst day yesterday, VRX remains controversial ... yet an excellent investment -- especially after yesterday's weakness. For a company with >20% exposure in Europe, to actually reaffirm the UPPER end of its EPS guidance is a testament to the strength and durability of its business model. We now lower our PT for a more realistic market."

Raises FY12 EPS Estimate from $4.21 to $4.59, FY13 from $5.00 to $5.22 and FY14 from $5.95 to $5.89.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $45.23 yesterday, with a 52 week range of $32.05-$59.94.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
• UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
• UBS Raises PT on Tesoro (TSO)

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?